{"title":"原发性纵隔大b细胞淋巴瘤","authors":"S. Knežević, Z. I. Gajović, M. Petrović","doi":"10.5937/PRAMED1901049K","DOIUrl":null,"url":null,"abstract":"ESSENTIAL: ● Hematopathology review of all slides with at least one paraffin block or 15 unstained slides representative of the tumor. Rebiopsy if consult material is nondiagnostic. ● Adequate morphology and immunophenotyping to establish diagnosis ○ Paraffin Panel: CD3, CD20 and/or another pan-B-cell marker (CD19, PAX-5, CD79a) or ○ Flow cytometry immunophenotypic studies: CD54 (LCA), CD3, CD5, CD10, CD19, CD20, CD22, kappa and lambda light chains ● Additional immunohistochemical studies to determine subgroup: PD-L1/L2, CD5, CD10, CD15, CD23, CD54, CD79a, BCL-2, BCL-6, MUM-1/IRF4, and MIB1 (Ki67),","PeriodicalId":31688,"journal":{"name":"Praxis Medica","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"8","resultStr":"{\"title\":\"Primary mediastinal large B-cell lymphoma\",\"authors\":\"S. Knežević, Z. I. Gajović, M. Petrović\",\"doi\":\"10.5937/PRAMED1901049K\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"ESSENTIAL: ● Hematopathology review of all slides with at least one paraffin block or 15 unstained slides representative of the tumor. Rebiopsy if consult material is nondiagnostic. ● Adequate morphology and immunophenotyping to establish diagnosis ○ Paraffin Panel: CD3, CD20 and/or another pan-B-cell marker (CD19, PAX-5, CD79a) or ○ Flow cytometry immunophenotypic studies: CD54 (LCA), CD3, CD5, CD10, CD19, CD20, CD22, kappa and lambda light chains ● Additional immunohistochemical studies to determine subgroup: PD-L1/L2, CD5, CD10, CD15, CD23, CD54, CD79a, BCL-2, BCL-6, MUM-1/IRF4, and MIB1 (Ki67),\",\"PeriodicalId\":31688,\"journal\":{\"name\":\"Praxis Medica\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"8\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Praxis Medica\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5937/PRAMED1901049K\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Praxis Medica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5937/PRAMED1901049K","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
ESSENTIAL: ● Hematopathology review of all slides with at least one paraffin block or 15 unstained slides representative of the tumor. Rebiopsy if consult material is nondiagnostic. ● Adequate morphology and immunophenotyping to establish diagnosis ○ Paraffin Panel: CD3, CD20 and/or another pan-B-cell marker (CD19, PAX-5, CD79a) or ○ Flow cytometry immunophenotypic studies: CD54 (LCA), CD3, CD5, CD10, CD19, CD20, CD22, kappa and lambda light chains ● Additional immunohistochemical studies to determine subgroup: PD-L1/L2, CD5, CD10, CD15, CD23, CD54, CD79a, BCL-2, BCL-6, MUM-1/IRF4, and MIB1 (Ki67),